Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders

Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Agonist Improves Coronary Artery Endothelial Function in Diabetic Patients with Coronary Artery Disease

(2013) J Yu et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity

(2011) Kensuke Toyama et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?

(2011) Pitchai Balakumar et al.   BRITISH JOURNAL OF PHARMACOLOGY

Guide to Receptors and Channels (GRAC), 5th edition

(2011) SPH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Leprfa/IzmDmcr rats with metabolic syndrome

(2011) Satomi Kagota et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Adiponectin Is Required for PPARγ-Mediated Improvement of Endothelial Function in Diabetic Mice

(2011) Wing Tak Wong et al.   Cell Metabolism

Preconditioning the hyperlipidemic myocardium: Fact or fantasy?

(2011) Pitchai Balakumar et al.   CELLULAR SIGNALLING

Telmisartan for the management of patients at high cardiovascular risk

(2011) Luis M. Ruilope   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

(2011) Kim Henriksen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Review of approved pioglitazone combinations for type 2 diabetes

(2011) Thomas Forst et al.   EXPERT OPINION ON PHARMACOTHERAPY

Endoplasmic Reticulum Ca2+Release Modulates Endothelial Nitric-oxide Synthase via Extracellular Signal-regulated Kinase (ERK) 1/2-mediated Serine 635 Phosphorylation

(2011) Zhihong Xiao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?

(2011) Pitchai Balakumar et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction

(2010) Tajpreet Kaur et al.   ARCHIVES OF PHARMACAL RESEARCH

Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase

(2010) Chi Yung Yuen et al.   CARDIOVASCULAR RESEARCH

The Novel Role of Fenofibrate in Preventing Nicotine- and Sodium Arsenite-Induced Vascular Endothelial Dysfunction in the Rat

(2010) Jagdeep Kaur et al.   Cardiovascular Toxicology

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects

(2010) Mi-Kyung Kim et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Oxidative stress modulates PPARγ in vascular endothelial cells

(2010) Carmelo Blanquicett et al.   FREE RADICAL BIOLOGY AND MEDICINE

Red wine: A source of potent ligands for peroxisome proliferator-activated receptor γ

(2010) Alfred Zoechling et al.   Food & Function

PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

(2009) Mi-Kyung Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products

(2009) Chun Liang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Thiazolidinediones and Congestive Heart Failure

(2009) Rujul R. Patel   Cardiology in Review

PPAR γ partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK

(2009) J. Kim et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

AMP-Activated Protein Kinase Functionally Phosphorylates Endothelial Nitric Oxide Synthase Ser633

(2009) Zhen Chen et al.   CIRCULATION RESEARCH

Vascular insulin resistance in prehypertensive rats: Role of PI3-kinase/Akt/eNOS signaling

(2009) Rong Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Telmisartan Decreases Plasma Levels of Asymmetrical Dimethyl-L-Arginine and Improves Lipid and Glucose Metabolism and Vascular Function

(2009) Yoshifumi Ono et al.   International Heart Journal

Up-regulating PPAR-γ expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: The possible antiatherogenic and antithrombotic effects of atorvastatin

(2009) Ping Yang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic Acid (MK-0533): A Novel Selective Peroxisome Proliferator-Activated Receptor γ Modulator for the Treatment of Type 2 Diabetes Mellitus with a Reduced Potential to Increase Plasma and Extracellular Fluid Volume

(2009) John J. Acton et al.   JOURNAL OF MEDICINAL CHEMISTRY

MBX-102/JNJ39659100, a Novel Peroxisome Proliferator-Activated Receptor-Ligand with Weak Transactivation Activity Retains Antidiabetic Properties in the Absence of Weight Gain and Edema

(2009) Francine M. Gregoire et al.   MOLECULAR ENDOCRINOLOGY

Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders?

(2009) Pitchai Balakumar et al.   PHARMACOLOGICAL RESEARCH

Cardioprotective Mechanism of Telmisartan via PPAR- -eNOS Pathway in Dahl Salt-Sensitive Hypertensive Rats

(2008) N. Kobayashi et al.   AMERICAN JOURNAL OF HYPERTENSION

Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts

(2008) Gabriella F. Kocsis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature

(2008) Sheng Zhong Duan et al.   CIRCULATION RESEARCH

A novel selective peroxisome proliferator-activator receptor-γ modulator—SPPARγM5 improves insulin sensitivity with diminished adverse cardiovascular effects

(2008) Ching H. Chang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats

(2008) Philip Wenzel et al.   FREE RADICAL BIOLOGY AND MEDICINE

Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-??-modulating activity, on nitric oxide bioavailability and atherosclerotic change

(2008) Hideyuki Ikejima et al.   JOURNAL OF HYPERTENSION

Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat

(2008) P BALAKUMAR et al.   PHARMACOLOGICAL RESEARCH

Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice

(2007) Po-Hsun Huang et al.   BIOMEDICINE & PHARMACOTHERAPY

Thiazolidinediones: effects on insulin resistance and the cardiovascular system

(2007) C E Quinn et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats

(2007) Seema Jindal et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions

(2007) Pitchai Balakumar et al.   TOXICOLOGY